Galapagos presents pre-clinical data with selective ADAMTS-5 inhibitor GLPG1972 for osteoarthritis at OARSI
(Thomson Reuters ONE) -
Mechelen, Belgium; 29 April 2017, 7.30 CET -Galapagos NV (Euronext & NASDAQ:
GLPG) announces presentation of pre-clinical pharmacology data with GLPG1972 at
the Osteoarthritis Research Society International (OARSI) annual meeting today
in Las Vegas, USA.
Galapagos and collaboration partner Servier are developing a potential disease-
modifying oral therapy for osteoarthritis with GLPG1972.
Galapagos today discloses that GLPG1972 is a potent and highly selective
inhibitor of ADAMTS-5, a well-established target in the literature for
osteoarthritis. ADAMTS-5 is a key enzyme involved in cartilage breakdown (Larkin
2015). At the OARSI 2017 World Congress, Galapagos presents pre-clinical
pharmacology data with GLPG1972 showing cartilage protection in both rodent and
human explant assays. Disease-modifying activity with GLPG1972 in the gold-
standard, destabilization of the medial meniscus (DMM) rodent model will also be
presented.
Galapagos previously announced that a Phase 1 study in healthy human volunteers
demonstrated favorable safety and PK profiles of GLPG1972, and up to 60%
reduction in a cartilage breakdown biomarker within two weeks of treatment. This
biomarker is serum ARGS-neoepitope, which is formed from cartilage through
ADAMTS-5 and thus serves as a biomarker for target engagement.
"Osteoarthritis is a disease with very limited treatment options, and none which
actually addresses the cause of the disease. By inhibiting ADAMTS-5, for which
the literature evidence is growing, GLPG1972 could play a central role in
osteoarthritis," said Dr Piet Wigerinck, Chief Scientific Officer of Galapagos.
"We are eager to see if we can repeat in patients the same impact on cartilage
breakdown biomarker ARGS-neoepitope as we saw in healthy volunteers."
In July 2010, Servier and Galapagos announced their alliance to develop
innnovative oral medicines for the treatment of osteoarthritis. Galapagos is
responsible for the discovery and development of new candidate drugs against
novel targets, and Servier has an exclusive option to license these candidates
after the completion of the Phase 1 trial and Phase 2A enabling activities.
Under this agreement, Galapagos is eligible to receive up to ?290 million in
success-based milestones, plus royalties on sales.
Galapagos plans to initiate a Phase 1b study in osteoarthritis patients in the
United States this quarter. Galapagos has the full US commercial rights in the
osteoarthritis collaboration with Servier.
Presentation title: "GLPG1972: A POTENT, SELECTIVE, ORALLY AVAILABLE ADAMTS-5
INHIBITOR FOR THE TREATMENT OF OA "
OARSI Session: Concurrent Session 8 - OA Treatments
Presentation Time: today at 11:55 AM - 12:05 PM MDT
About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company
specialized in the discovery and development of small molecule medicines with
novel modes of action. Our pipeline comprises Phase 3, Phase 2, Phase 1, pre-
clinical, and discovery programs in cystic fibrosis, inflammation, fibrosis,
osteoarthritis and other indications. We have discovered and developed
filgotinib: in collaboration with Gilead we aim to bring this JAK1-selective
inhibitor for inflammatory indications to patients all over the world. Galapagos
is focused on the development and commercialization of novel medicines that will
improve people's lives. The Galapagos group, including fee-for-service
subsidiary Fidelta, has approximately 530 employees, operating from its
Mechelen, Belgium headquarters and facilities in The Netherlands, France, and
Croatia. More information at www.glpg.com.
Contacts
Investors: Media:
Elizabeth Goodwin Evelyn Fox
VP IR & Corporate Communications Director Communications
+1 781 460 1784 +31 6 53 591 999
communications(at)glpg.com
Paul van der Horst
Director IR & Business Development
+31 6 53 725 199
ir(at)glpg.com
Forward-looking statements
This release may contain forward-looking statements, including statements
regarding Galapagos' strategic ambitions, the mechanism of action and profile of
GLPG1972, the anticipated timing of clinical studies with GLPG1972 and the
progression and results of such studies. Galapagos cautions the reader that
forward-looking statements are not guarantees of future performance. Forward-
looking statements involve known and unknown risks, uncertainties and other
factors which might cause the actual results, financial condition and liquidity,
performance or achievements of Galapagos, or industry results, to be materially
different from any historic or future results, financial conditions and
liquidity, performance or achievements expressed or implied by such forward-
looking statements. In addition, even if Galapagos' results, performance,
financial condition and liquidity, and the development of the industry in which
it operates are consistent with such forward-looking statements, they may not be
predictive of results or developments in future periods. Among the factors that
may result in differences are the inherent uncertainties associated with
competitive developments, clinical trial and product development activities and
regulatory approval requirements (including that data from the ongoing and
planned clinical research programs may not support registration or further
development of GLPG1972 due to safety, efficacy or other reasons), Galapagos'
reliance on collaborations with third parties (including its collaboration
partner for GLPG1972, Servier), and estimating the commercial potential of
Galapagos' product candidates. A further list and description of these risks,
uncertainties and other risks can be found in Galapagos' Securities and Exchange
Commission (SEC) filings and reports, including in Galapagos' most recent annual
report on form 20-F filed with the SEC and subsequent filings and reports filed
by Galapagos with the SEC. Given these uncertainties, the reader is advised not
to place any undue reliance on such forward-looking statements. These forward-
looking statements speak only as of the date of publication of this document.
Galapagos expressly disclaims any obligation to update any such forward-looking
statements in this document to reflect any change in its expectations with
regard thereto or any change in events, conditions or circumstances on which any
such statement is based or that may affect the likelihood that actual results
will differ from those set forth in the forward-looking statements, unless
specifically required by law or regulation.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Galapagos NV via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 29.04.2017 - 07:30 Uhr
Sprache: Deutsch
News-ID 539194
Anzahl Zeichen: 7829
contact information:
Town:
Mechelen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 370 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Galapagos presents pre-clinical data with selective ADAMTS-5 inhibitor GLPG1972 for osteoarthritis at OARSI"
steht unter der journalistisch-redaktionellen Verantwortung von
Galapagos NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
